Efficacy and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis patients: a systematic review and meta-analysis of randomised controlled trials.
Wenjuan WuLingxiao QiuJizhen WuXueya LiuGuojun ZhangPublished in: BMJ open (2021)
Pirfenidone can provide survival benefit for patients with IPF. Pirfenidone treatment was also associated with a longer PFS, a lower incidence of acute exacerbation and worsening of IPF.
Keyphrases
- idiopathic pulmonary fibrosis
- interstitial lung disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- liver failure
- respiratory failure
- intensive care unit
- combination therapy
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- patient reported
- free survival
- mechanical ventilation
- pulmonary fibrosis